Research
Hormonal
Metabolic endotoxemia, driven by lipopolysaccharides (LPS) from Gram-negative bacteria translocating into the bloodstream, causes systemic inflammation and insulin resistance.
Reducing high-fat diets may help lower LPS levels and systemic inflammation. A diet that supports gut barrier integrity (e.g., through fiber and prebiotics) may help reduce metabolic endotoxemia and improve insulin sensitivity.
ModerateSupportsMEDIUM confidence
The lipopolysaccharides (LPS) are endotoxins commonly found in the outer membrane of Gram-negative bacteria that cause metabolic endotoxemia, which is characterized by the release of proinflammatory molecules... this increase is directly related with the degree of insulin resistance.
Why this rating
Supported by animal studies showing LPS infusion induces insulin resistance, and human studies showing elevated LPS in obese/diabetic subjects.
Source
Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus
Isabel Moreno‐Indias et al. · Frontiers in Microbiology · 2014
DOI 10.3389/fmicb.2014.00190
narrative_reviewCited 308×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- An altered gut microbiota composition, specifically an increased Firmicutes-to-Bacteroidetes ratio, enhances energy harvest from the diet, contributing to obesity and metabolic disorders.Moderate
- Short-chain fatty acids (SCFAs), particularly butyrate, produced by gut bacteria, have protective effects against metabolic diseases by improving gut barrier function and reducing inflammation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →